Latest Intelligence on Oncology in Europe

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Schering AG/Novartis: cancer drug hopes hit

Schering AG and Novartis have announced that a late stage trial of PTK787 did not reach statistical significance in terms of progression-free survival. The setback is expected to delay the filing for PTK787 in first line to early 2007, and shares in Schering plunged as result. The news will only serve to reinforce rival drug Avastin's increasingly dominant position in the colorectal cancer market.

Published By Datamonitor
21 Mar 2005
CommentWire
CommentWire

Genta: Genasense on a rocky road

Sanofi-Aventis [SAN.PA] told Genta [GNTA] that it intended to end the collaboration between the two for the development of Genasense back in November 2004 after the drug failed to gain approval for chronic lymphoid leukemia, malignant melanoma and multiple myeloma. Although the drug remains in clinical trials, Genasense is unlikely to fulfill the commercial potential it once promised.

Published By Datamonitor
11 May 2005
CommentWire
CommentWire

Schering-Plough: soft impact for extended Temodal approval

Schering-Plough's Temodal has been approved in the EU for the first-line treatment of glioblastoma multiforme (GBM) in combination with radiotherapy, following US approval in March. However, as the drug has already been in use off-label for previously-untreated GBM patients, there is unlikely to be a substantial surge in sales of Temodal in the EU.

Published By Datamonitor
14 Jun 2005
CommentWire
CommentWire

OSI / Roche / Genentech: European approval would confirm Tarceva's lead

An EMEA committee has recommended approval of Tarceva in an advanced non-small cell lung cancer (NSCLC) indication. If granted, the approval should make Tarceva the leading drug of its kind in the lung cancer market, as well as strengthening OSI, Genentech and Roche's positions in oncology.

Published By Datamonitor
27 Jun 2005
CommentWire
CommentWire

Roche: buying up for biotech boost

Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.

Published By Datamonitor
20 Jul 2005
CommentWire
CommentWire

Bayer/Onyx: kidney cancer battle too early to call

Bayer and Onyx have submitted an EU marketing application for sorafenib in previously treated renal cell carcinoma. While an approval would obviously please its manufacturers, the drug's chances in the market are rather difficult to assess. Although Pfizer's Sutent appears superior in terms of efficacy, the lack of large-scale trial data makes it difficult to differentiate between the two drugs.

Published By Datamonitor
12 Sep 2005
CommentWire
CommentWire

OSI / Genentech / Roche: Tarceva triumphs again

The results of a phase II study have suggested that OSI Pharmaceuticals, Genentech and Roche's Tarceva may be particularly beneficial in elderly patients with previously untreated lung cancer. These results may increase off-label first-line use of the drug in such patients, although Tarceva's high price may hinder uptake in this setting.

Published By Datamonitor
19 Sep 2005
ResearchWire
ResearchWire

Cancer therapies: cytotoxics rise and fall

Published By Datamonitor
23 Sep 2005
CommentWire
CommentWire

Schering-Plough: Temodar strengthens its base

New data have shown that Schering-Plough's Temodar/Temodal plus radiotherapy significantly improved median and two-year survival in patients with newly diagnosed glioblastoma multiforme. The results should accelerate uptake of Temodar, which will be crucial as Schering-Plough needs to act fast to maximize the drug's uptake in Europe before its patent expires in 2007.

Published By Datamonitor
31 Oct 2005
Expert View
Expert View

AstraZeneca on the acquisition trail

UK drug manufacturer AstraZeneca ended 2005 on a high note, making four significant acquisitions in December. This spending spree comprised the acquisition of product rights for one phase III drug and two phase II products, alongside the purchase of UK-based biotech firm KuDOS Pharmaceuticals. With these purchases, AstraZeneca aims to bolster its pipeline in both the short and long term.

Published By Datamonitor
04 Jan 2006

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.